NF-κB: Arresting a major culprit in cancer

Drug Discovery Today

Volumn 7, Issue 12, 2002, Pages 653-663

  Haefner, Burkhard ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; AMIDE; AS 2868; AS 602868; BATIMASTAT; BENZIMIDAZOLE DERIVATIVE; BETA CARBOLINE DERIVATIVE; BORTEZOMIB; CT 98014; CT 98023; CT 99021; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLE DERIVATIVE; IRINOTECAN; MALEIMIDE DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; NVPIKK 004; NVPIKK 005; PROTEIN KINASE INHIBITOR; PROTEIN P53; SB 410111; SB 495052; SB 517955; SPC 0023579; SPC 839; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT;

ANEMIA; APOPTOSIS; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CARCINOMA; CELL TRANSFORMATION; CHILL; CLINICAL TRIAL; DRUG INDUSTRY; DRUG TARGETING; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOTENSION; INFLAMMATION; LEUKOPENIA; MOLECULAR SIZE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN FUNCTION; REVIEW; THROMBOCYTOPENIA; DRUG ANTAGONISM; DRUG DESIGN; IMMUNOLOGY; NECROSIS; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG DESIGN; HUMAN; NECROSIS; NEOPLASMS; NF-KAPPA B; HUMANS;

EID: 0037096221     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(02)02309-7     Document Type: Review

References (106)

1. NF-κB in cancer: From innocent bystander to major culprit
2. Tumors: Wounds that do not heal
3. Chronic immune activation and inflammation as the cause of malignancy
4. Inflammation and cancer: Back to Virchow?
5. Plasma levels of TNF-a and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients
6. Serum levels of TNF-a and soluble interleukin receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma
7. TNF-a: Roles in cancer pathophysiology
8. Mice deficient in TNFα are resistant to skin carcinogenesis
9. Paradoxical effects of TNF-a in experimental ovarian cancer
10. NSAIDs and gastrointestinal cancer prevention
11. Phosphorylation meets ubiquitination: The control of NF-κB activity
12. Isolation of the avian reticuloendothelial virus (strain T)
13. Rel/NF-κB/IκB proteins and cancer
14. Aberrant Rel/NF-κB genes and activity in human cancer
15. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity, which is required for cellular transformation
16. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras
17. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
18. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1
19. New insights into the role of NF-κB in cell growth regulation
20. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
21. Epidermal growth factor-induced NF-κB activation: A major pathway of cell cycle progression in estrogen-receptor negative breast cancer cells
22. The nuclear factor-κB: A potential therapeutic target for estrogen receptor negative breast cancers
23. Soy isoflavone supplementation in healthy men prevents NF-κB activation by TNFα in blood lymphocytes
24. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase
25. Inhibitory effects of curcumin and capsaicin on phorbol ester-induced activation of eukaryotic transcription factors, NF-κB and AP-1
26. Tumour necrosis factor and cancer
27. Coley's toxin, tumor necrosis factor and cancer research: A historical perspective
28. An endotoxin-induced serum factor that causes necrosis of tumours
29. An overview on the use of TNFα: Our experience with regional administration and developments towards new opportunities for systemic application
30. A new method of antitumour therapy with a high dose of TNF-a perfusion for unresectable liver tumours
31. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
32. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of NF-κB activation
33. Inhibition of NF-κB sensitizes non-small lung cancer cells to chemotherapy-induced apoptosis
34. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic NF-κB inhibition
35. Proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in lung adenocarcinoma cell line
36. TNF-a- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB
37. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB
38. Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin
39. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line
40. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism
41. Role of NF-κB in p53-mediated programmed cell death
42. NF-κB-mediated induction of mdr1b expression by insulin in hepatoma cells
43. Induction of Mdr1b expression by TNFα in rat liver cells is independent of p53 but requires NF-κB signaling
44. Mechanisms of resistance to imatinib (STI571) and prospects of combination with conventional chemotherapeutic agents
45. New-age drug meets resistance
46. The role of cytokines in cancer cachexia
47. Intratumoral injection of oligonucleotides to the NF-κB site inhibits cachexia in a mouse tumor model
48. NF-κB-induced loss of MyoD messenger RNA possible role in muscle decay and cachexia
49. The TRAIL to an anti-cancer agent
50. The use of TNF-a family ligands and receptors and agents which modify their interaction as therapeutic agents
51. The potential of TRAIL for cancer chemotherapy
52. Inhibition of NF-κB activity enhances TRAIL-mediated apoptosis in breast cancer cells
53. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumour therapy
54. Suppression of TNFα-induced MMP-9 production by the introduction of a super-repressor form of IκBα cDNA into immortalized human salivary gland acinar cells. Prevention of the destruction of the acinar structure in Sjorgen's syndrome salivar glands
55. Effective adenoviral transfer of IκBα into human fibroblasts and chondrosarcoma cells reveals that the induction of MMPs and proinflammatory cytokines is NF-κB dependent
56. The IκB kinase (IKK) and NF-κB: Key elements of proinflammatory signalling
57. Activation of NF-κB and Bcl-x survival gene expression by nerve growth factor requires tyrosine phosphorylation of IκBα
58. Requirement for GSK-3β in cell survival and NF-κB activation
59. Wnt signaling and cancer
60. Structure of GSK-3β reveals a primed phosphorylation mechanism
61. The structure of phosphorylated GSK-3β complexed with a peptide, FRATide, that inhibits β-catenin phosphorylation
62. The renaissance of GSK-3
63. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism
64. Activation of nuclear transcription factor NF-κB by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit
65. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300
66. ras and protein kinase Cζ in primary endothelial cells
67. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-κB-dependent gene transciption
68. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain
69. Distinct roles of the IκB kinase α and β subunits in liberating NF-κB from IκB and in phosphorylating the p65 subunit of NF-κB
70. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IKKβ
71. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IKKα and β
72. Inhibition of IκB kinase activity by sodium salicylate in vitro does not reflect its inhibitory mechanism in intact cells
73. Constitutive activation of IKKα and NF-κB in prostate cancer cells is inhibited by ibuprofen
74. Sulindac inhibits activation of the NF-κB pathway
75. Inhibition of NF-κB activity by thalidomide through suppression of IKK activity
76. Thalidomide: A novel template for anticancer drugs
77. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IKK and NF-κB activation in macrophages
78. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IKK
79. IKKα and β show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin
80. Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IKK
81. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells
82. The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs
83. Proteasome regulation of activation-induced T cell death
84. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome
85. The immunosuppressive fungal metabolite gliotoxin specifically inhibits transcription factor NF-κB
86. Inhibition of farnesyl transferase by gliotoxin and acetylgliotoxin
87. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway
88. NF-κB as a therapeutic target in multiple myelome
89. Selective small molecule inhibitors of GSK-3 modulate glycogen metabolism and gene transcription
90. Selective small-molecule inhibitors of GSK-3 activity protect primary neurones from death